Key facts
- It has raised $6.4M; the latest was Later Stage VC ($4.1M) in Nov 2025.
- Notable investors include NCBR Investment Fund, CofounderZone, Forum TFI, Kvarko Group, Nanogroup — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Auxilius Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Auxilius Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Auxilius Pharma
Operator of a pharmaceutical company intended to focus on optimizing and further developing well-established medications. The company specializes in the formulation of generic oncological drugs in a convenient dosage form, enabling medical professionals to find therapies to treat cancer patients.
- Sector
- Healthcare
- HQ
- Warsaw, Poland
- Founded
- 2018
- Employees
- 6
- Website
- auxiliuspharma.com/
- Ownership
- Privately Held (backing)
Auxilius Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Auxilius Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Auxilius Pharma in its N-PORT filings yet. We sweep new filings monthly.